Dr Tobias Menne
| Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial | 2024 |
|
Dr Tobias Menne
Dr Wendy Osborne
| Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time | 2024 |
|
Dr Tobias Menne
Professor Anthony Moorman
| Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial | 2022 |
|
Dr Wei-yu Lin
Dr Sarah Fordham
Dr Nicola Sunter
Dr Claire Elstob
Dr Yaobo Xu
et al. | Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (Nature Communications, (2021), 12, 1, (6233), 10.1038/s41467-021-26551-x) | 2022 |
|
Dr Tobias Menne
Dr Wendy Osborne
Dr George Petrides
| Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma | 2022 |
|
Dr Tobias Menne
| Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study | 2022 |
|
Dr Tom Creasey
Emilio Barretta
Dr Sarra Ryan
Ellie Butler
Dr Daniel Leongamornlert
et al. | Genetic and genomic analysis of acute lymphoblastic leukaemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials | 2022 |
|
Dr Tobias Menne
| Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study | 2022 |
|
Dr Tobias Menne
Professor Anthony Moorman
| In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial | 2022 |
|
Professor Anthony Moorman
Emilio Barretta
Ellie Butler
Eleanor Ward
Dr Amir Enshaei
et al. | Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study | 2022 |
|
Dr Tobias Menne
Professor Julie Irving
Professor Ruth Plummer
Dr Geoff Shenton
Professor Gareth Veal
et al. | Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial | 2022 |
|
Dr Tobias Menne
| Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial | 2021 |
|
Dr Tobias Menne
| Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients — A British Society for Haematology Guideline | 2021 |
|
Dr Wei-Yu Lin
Dr Sarah Fordham
Dr Nicola Sunter
Dr Claire Elstob
Dr Yaobo Xu
et al. | Genome-wide association study identifies susceptibility loci for acute myeloid leukemia | 2021 |
|
Emilio Barretta
Dr Tobias Menne
Professor Anthony Moorman
| IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial | 2021 |
|
Dr Tobias Menne
| Radiotherapy Bridging in Patients With R/R High-Grade Lymphoma Receiving CD19 CAR-T in the UK | 2021 |
|
Professor Anthony Moorman
Dr Amir Enshaei
Dr Tobias Menne
| Clinical Efficacy of a Novel Validated Prognostic Index for Trial Design in Adult Acute Lymphoblastic Leukaemia | 2019 |
|
